Published September 16, 2015 5:06pm EDT | Updated September 16, 2015 6:06pm EDT

Aerie Pharma Shares Skyrocket On Glaucoma Drug Study Results

Aerie Pharmaceuticals Inc. shares skyrocketed late Wednesday after the drug developer said its glaucoma treatment met its primary endpoint in a late-stage clinical trial. Aerie shares surged 70% to $30.59 on heavy volume. The company said its glaucoma treatment Rhopressa worked just as well as another treatment, timolol. Aerie said it expects to file a marketing application for Rhopressa with the Food and Drug Administration in mid-2016.